SCHEMBL14959893

SCHEMBL14959893

Cc1ccc([C@H]2CC[C@H](CF)CC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 10/20 0.44
ESR1 P03372 6/20 0.44
CYP2C9 P11712 3/20 0.44
CYP3A4 P08684 2/20 0.44
SLC18A3 Q16572 1/20 0.40
CYP2D6 P10635 1/20 0.40
ALDH1A1 P00352 2/20 0.37
LMNA P02545 2/20 0.37
MAPT P10636 2/20 0.37
TP53 P04637 1/20 0.37
ATM Q13315 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14959891 1.00 ESR2 (0.44) ESR2ESR1CYP2C9CYP3A4SLC18A3
SCHEMBL7910977 0.90 ESR2 (0.42) ESR2ESR1CYP2C9CYP3A4SLC18A3
SCHEMBL7910978 0.90 ESR2 (0.42) ESR2ESR1CYP2C9CYP3A4SLC18A3
SCHEMBL7910974 0.90 ESR2 (0.42) ESR2ESR1CYP2C9CYP3A4SLC18A3
SCHEMBL7910979 0.90 ESR2 (0.42) ESR2ESR1CYP2C9CYP3A4SLC18A3
SCHEMBL12918542 0.84 ESR2 (0.57) ESR2ESR1CYP2C9CYP3A4CYP2D6
SCHEMBL1405569 0.82 ESR2 (0.50) ESR2ESR1CYP2C9CYP3A4SLC18A3
SCHEMBL10607267 0.82 ESR2 (0.46) ESR2ESR1CYP2C9CYP3A4SLC18A3
SCHEMBL28710893 0.80 ESR2 (0.69) ESR2ESR1CYP2C9CYP3A4SLC18A3
SCHEMBL18666373 0.80 ESR2 (0.44) ESR2ESR1CYP2C9CYP3A4SLC18A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594270-A2 The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) BIP Patents (DE) 2013-05-22 EP disclosed